Limitations, agreements, and source contact

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) · Source last updated 2026-07-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

true

point Of Contact

email

service@emdgroup.com

organization

Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany

phone

+49-6151-72-5200

title

Communication Center

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice